Jean-Charles Soria discusses future treatments for selected lung cancer patients. These studies were presented during ESMO 2012, the Congress of the European Society for Medical Oncology.
ESMO 2012
Share
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Select a Section…
1
Abstract
Overview
Jean-Charles Soria discusses future treatments for selected lung cancer patients. These studies were presented during ESMO 2012, the Congress of the European Society for Medical Oncology. Read all the news about the latest in cancer and oncology from the Congress here
https://www.esmo.org/events/vienna-2012-congress/congress-news.html
The opinion expressed in this interview reflects that of the interviewee and does not necessarily express the official ESMO point of view.
Keywords
Jean-Charles Soria discusses future treatments for selected lung cancer patients. These studies were presented during ESMO 2012, the Congress of the European Society for Medical Oncology.
2
Article
2
References
Jean-Charles Soria | ESMO/a>
3
Article Information
Received
2011-03-01T00:00:00
4
Further Resources
Trending Topic
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Highlights Immunotherapy, especially combinatory immunotherapy, has shown promise with prolonged survival for patients with advanced mesothelioma in the first-line setting (see the sections on ‘Systemic treatment and immunotherapy debut’ and ‘Randomized immunotherapy trials of mesothelioma’). Histology-based therapy is important to consider, with non-epithelioid subtypes responding better to immunotherapy than to chemotherapy (see the section on […]
Mark CompleteCompleted
BookmarkBookmarked
Welcome to the latest issue of touchREVIEWS in Oncology & Haematology. We are honoured to present a series of compelling articles that reflect cutting-edge developments and diverse perspectives in this ever-evolving field. This issue includes a series of editorials and ...
Mark CompleteCompleted
BookmarkBookmarked
Unmet clinical needs for patients with advanced epidermal growth factor receptor-mutated non–small-cell lung cancer Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) have become the standard first-line therapy for patients with advanced non–small-cell lung cancer (NSCLC) harbouring ...
Mark CompleteCompleted
BookmarkBookmarked
Accurately detecting lung tumours and their margins is important for disease outcomes.1,2 However, detection is challenging due to the use of minimally invasive surgery and current localization techniques, such as computed tomography (CT)-guided and endobronchial interventions, which add significantly ...
Mark CompleteCompleted
BookmarkBookmarked
Cancer treatment has expanded rapidly in recent years as advancements in the fields of tumour biology and molecular diagnostics have informed the development of targeted therapies, improving survival in patients with oncogene-addicted cancers with therapeutically relevant molecular lesions. Osimertinib has ...
Mark CompleteCompleted
BookmarkBookmarked
The treatment of patients with non-small cell lung cancer (NSCLC) has seen significant advances in the past decade, with the availability of multiple targeted therapy agents for oncogenic-driven non-squamous NSCLC and the advent of immunotherapy that has completely revolutionized the ...
Mark CompleteCompleted
BookmarkBookmarked
Advanced non-small cell lung carcinoma (NSCLC) treatment paradigms have evolved during the past decade. Identification of tumor-specific molecular alteration in cancer driver genes has led to the development of targeted therapies.1–3 Most of the tumors harboring such alterations are sensitive ...
Mark CompleteCompleted
BookmarkBookmarked
NEW
Radiation-induced esophagitis, caused by incidental damage to the mucosal lining of the esophagus during radiation therapy, is a common and clinically important toxicity in patients with lung cancer. Esophagitis generally develops 2–3 weeks after initiation of radiation therapy and presents as ...
Mark CompleteCompleted
BookmarkBookmarked
NEW
Historically, chemotherapy represented the only available treatment for patients with advanced non-small-cell lung cancer (NSCLC) who did not show any target molecular driver, such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) or the receptor tyrosine kinase ROS1. ...
Mark CompleteCompleted
BookmarkBookmarked
At initial diagnosis of metastatic disease, central nervous system (CNS) metastases are present in 22–33% of patients with anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC). After crizotinib failure, the incidence can reach up to 70%, compared with 40% in ...
Mark CompleteCompleted
BookmarkBookmarked
Non-small cell lung cancer (NSCLC) remains a world-wide health issue, accounting for 85% of all lung cancers, of which there were an estimated 2.1 million new cases and 1.76 million deaths in 2018; equivalent to 11.6% of the global cancer burden.1,2Â This incidence is expected ...
Mark CompleteCompleted
BookmarkBookmarked
Welcome to the fall edition of Oncology and Hematology Review (US), which features a wide variety of articles covering topics of interest to oncologists and hematologists, as well as the wider medical community. We begin with some expert interviews, which ...
Mark CompleteCompleted
BookmarkBookmarked
Lung cancer is the leading cause of cancer deaths in the USA. In 2018 an estimated 154,050 Americans were predicted to die from lung cancer, accounting for approximately 25% of all cancer deaths.1 However, recent advances have transformed early diagnosis and the treatment ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
